Orthocell CEO and Managing Director Paul Anderson joins Proactive Newsroom to reflect on a landmark year for the company, headlined by FDA approval of its nerve repair product Remplir and record revenue growth. Anderson discusses strong surgeon uptake, real-world patient outcomes, first US procedures, and a $30 million capital raise that positions Orthocell for expansion in the Americas, with growing revenue momentum expected into 2026.
#Orthocell #PaulAnderson #ProactiveNewsroom #ASX #MedTech #RegenerativeMedicine #FDAApproval #HealthcareInnovation #MedicalDevices #Biotechnology #ASXStocks